Papillary thyroid carcinoma oncogene (RET/PTC) alters the nuclear envelope and chromatin structure

American Journal of Pathology

Volumn 153, Issue 5, 1998, Pages 1443-1450

  Fischer, Andrew H ^a   Bond, Jane A ^b   Taysavang, Panya ^a   Battles, O Eugene ^a   Wynford Thomas, David ^b  

^a EMORY UNIVERSITY HOSPITAL   (United States)

^b CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CELL NUCLEUS MEMBRANE; CHROMATIN; CHROMATIN STRUCTURE; GENE EXPRESSION; GENE TRANSFER; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; ONCOGENE; PRIORITY JOURNAL; SCORING SYSTEM; THYROID CARCINOMA;

EID: 0031768031     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65731-8     Document Type: Article

References (49)

1. LiVolsi VA: Surgical Pathology of the Thyroid, vol. 22 in series Major Problems in Pathology. Edited by Bennington JL. Philadelphia, WB Saunders, 1990
2. Rosai J, Carcangiu ML, Delellis RA: Tumors of the Thyroid Gland, Fascicle 5, third series. Edited by Rosai J, Sobin LH. Washington, DC, Armed Forces Institute of Pathology, 1992
3. Franssila KO, Ackerman LV, Brown CL, Hedinger CE: Follicular carcinoma. Semin Diagn Pathol 1985, 2:101-122
4. Lemoine NR, Mayall ES, Wyllie FS, Williams ED, Goyns M, Stringer B, Wynford-Thomas D: High frequency of ras oncogene activation in all stages of human thyroid tumorigenesis. Oncogene 1989, 4:159-164
5. Wright PA, Lemoine NR, Mayall ES, Wyllie FS, Hughes D, Williams ED, Wynford-Thomas D: Papillary and follicular thyroid carcinomas show a different pattern of ras oncogene mutation. Br J Cancer 1989, 60:576-577
6. Santoro M, Carlomagno F, Hay ID, Herrmann MA, Grieco M, Melillo R, Pierotti MA, Bongarzone I, Della Porta G, Berger N, Peix JL, Paulin C, Fabien N, Vecchio G, Jenkins RB, Fusco A: Ret oncogene activation in human thyroid neoplasms is restricted to the papillary cancer subtype. J Clin Invest 1992, 89:1517-1522
7. Santoro M, Grieco M, Melillo RM, Fusco A, Vecchio G: Molecular defects in thyroid carcinomas: role of the RET oncogene in thyroid neoplastic transformation. Eur J Endocrinol 1995, 133:513-522
8. Wynford-Thomas D: Origin and progression of thyroid epithelial tumours: cellular and molecular mechanisms. Hormone Res 1997, 47:145-157
9. Johannessen JV, Sobrinho-Simoes M: Well differentiated thyroid tumors: problems in diagnosis and understanding. Pathol Annu 1983, 18:255-285
10. Salmon I, Kiss R, Franc B, Gasperin P, Heimann R, Pasteels JL, Verhest A: Comparison of morphonuclear features in normal, benign and neoplastic thyroid tissue by digital cell image analysis. Anal Quant Cytol Histol 1992, 14:47-54
11. Vickery AL Jr, Carcangiu ML, Johannessen JV, Sobrinho-Simoes M: Papillary carcinoma. Semin Diagn Pathol 1985, 2:90-100
12. Hay ID, Grant CS, van Heerden JA, Goellner JR, Ebersold JR, Bergstralh EJ: Papillary thyroid microcarcinoma: a study of 535 cases observed in a 50-year period. Surgery 1992, 112:1139-1147
13. Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis JC, Hu S, Altrock BW, Fox GM: GDNF-induced activation of the ret protein tyrosine kinase is mediated by GDNFR-α, a novel receptor for GDNF. Cell 1996, 85:1113-1124
14. Santoro M, Sabino N, Ishizaka Y, Ushijima T, Carlomagno F, Cerrato A, Grieco M, Battaglia C, Martelli ML, Paulin C, Fabien N, Sugimura T, Fusco A, Nagao M: Involvement of RET oncogene in human tumours: specificity of RET activation to thyroid tumours. Br J Cancer 1993, 68:460-464
15. Ishizaka Y, Kobayashi S, Ushijima T, Hirohashi S, Sugimura T, Nagao M: Detection of retTPC/PTC transcripts in thyroid adenomas and adenomatous goiter by an RT-PCR method. Oncogene 1991, 6:1667-1672
16. Bounacer A, Wicker R, Caillou B, Cailleux AF, Sarasin A, Schlumberger M, Suarez HG: High prevalence of activating ret proto-oncogene rearrangements in thyroid tumors from patients who had received external radiation. Oncogene 1997, 15:1263-1273
17. Jhiang SM, Mazzaferri EL: The ret/PTC oncogene in papillary thyroid carcinoma. J Lab Clin Med 1994, 123:331-337
18. Jhiang SM, Smanik PA, Mazzaferri EL: Development of a single-step duplex RT-PCR detecting different forms of ret activation and identification of the third form of in vivo ret activation in human papillary thyroid carcinoma. Cancer Lett 1994, 78:69-76
19. Viglietto G, Chiappetta G, Martinez-Tello FJ, Fukunaga FH, Tallini G, Rigopoulou D, Visconti R, Mastro A, Santoro M, Fusco A: RET/PTC oncogene activation is an early event in thyroid carcinogenesis. Oncogene 1995, 11:1207-1210
20. Tong Q, King S, Jhiang SM: Leucine zipper-mediated dimerization is essential for the PTC1 oncogenic activity. J Biol Chem 1997, 272: 9043-9047
21. Durick K, Yao VJ, Borrello MG, Bongarzone I, Pierotti MA, Taylor SS: Tyrosines outside the kinase core and dimerization are required for the mitogenic activity of RET/ptc2. J Biol Chem 1995, 270:24642-24645
22. Klugbauer S, Demidchik EP, Lengfelder E, Rabes HM: Detection of a novel type of RET rearrangement (PTC5) in thyroid carcinomas after Chernobyl and analysis of the involved RET-fused gene RFG5. Cancer Res 1998, 58:198-203
23. Ishizaka Y, Shima H, Sugimura T, Nagao M: Detection of phosphorylated retTPC oncogene product in cytoplasm. Oncogene 1992, 7:1441-1444
24. Ito T, Seyama T, Iwamoto KS, Mizuno T, Tronko ND, Komissarenko IV, Cherstovoy ED, Satow Y, Takeichi N, Dohi K, Akiyama M: Activated RET oncogene in thyroid cancers of children from areas contaminated by Chernobyl accident. Lancet 1994, 344:259
25. Klugbauer S, Lengfelder E, Demidchik EP, Rabes HM: High prevalence of RET rearrangement in thyroid tumors of children from Belarus after the Chernobyl reactor accident. Oncogene 1995, 11:2459-2467
26. Tallini G, Santoro M, Helie M, Carlomagno F, Salvatore G, Chiappetta G, Carcangiu ML, Fusco A: RET/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes. Clin Cancer Res 1998, 4:287-294
27. Roque L, Clode AL, Gomes P, Rosa-Santos J, Soares J, Castedo S: Cytogenetic findings in 31 papillary thyroid carcinomas. Genes Chromosomes & Cancer 1995, 13:157-162
28. Sozzi G, Bongarzone I, Miozzo M, Cariani CT, Mondellini P, Calderone C, Pilotti S, Pierotti MA, Della Porta G: Cytogenetic and molecular genetic characterization of papillary thyroid carcinomas. Genes Chromosomes & Cancer 1992, 5:212-218
29. Sozzi G, Bongarzone I, Miozzo M, Borrello MG, Blutti MG, Pilotti S, Della Porta G, Pierotti MA: A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma. Genes Chromosomes & Cancer 1994, 9:244-250
30. Jhiang SM, Sagartz JE, Tong Q, Parker-Thornburg J, Capen CC, Cho JY, Xing S, Ledent C: Targeted expression of the ret/PTC1 oncogene induces papillary thyroid carcinomas. Endocrinology 1996, 137:375-378
31. Santoro M, Chiappetta G, Cerrato A, Salvatore D, Zhang L, Manzo G, Picone A, Portella G, Santelli G, Vecchio G, Fusco A: Development of thyroid papillary carcinomas secondary to tissue-specific expression of the RET/PTC1 oncogene in transgenic mice. Oncogene 1996, 12:1821-1826
32. Bond JA, Wyllie FS, Rowson J, Radulescu A, Wynford-Thomas D: In vitro reconstruction of tumour initiation in a human epithelium. Oncogene 1994, 9:281-290
33. Rees S, Coote J, Stables J, Goodson S, Harris S, Lee MG: Bicistronic vector for the creation of stable mammalian cell lines that predisposes all antibiotic-resistant cells to express recombinant protein. Biotechniques 1996, 20:102-110
34. Pierotti MA, Bongarzone I, Borrello MG, Mariani C, Miranda C, Sozzi G, Greco A: Rearrangements of TRK proto-oncogene in papillary thyroid carcinomas. J Endocrinol Invest 1995, 18:130-133
35. Greco A, Fusetti L, Miranda C, Villa R, Zanotti S, Pagliardini S, Pierotti MA: Role of the TFG N-terminus and coiled-coil domain in the transforming activity of the thyroid TRK-T3 oncogene. Oncogene 1998, 16:809-816
36. Borrello MG, Pelicci G, Arighi E, De Filippis L, Greco A, Bongarzone I, Rizzetti M, Pelicci PG, Pierotti MA: The oncogenic versions of the Ret and Trk tyrosine kinases bind Shc and Grb2 adaptor proteins. Oncogene 1994, 9:1661-1668
37. Greco A, Pierotti MA, Bongarzone I, Pagliardini S, Lanzi C, Della Porta G: TRK-T1 is a novel oncogene formed by the fusion of TPR and TRK genes in human papillary thyroid carcinomas. Oncogene 1992, 7:237-242
38. Califano D, Monaco C, de Vita G, A DA, Dathan NA, Possenti R, Vecchio G, Fusco A, Santoro M, de Franciscis V: Activated RET/PTC oncogene elicits immediate early and delayed response genes in PC12 cells. Oncogene 1995, 11:107-112
39. Greco A, Orlandi R, Mariani C, Miranda C, Borrello MG, Cattaneo A, Pagliardini S, Pierotti MA: Expression of TRK-T1 oncogene induces differentiation of PC12 cells. Cell Growth Differ 1993, 4:539-546
40. Santoro M, Melillo RM, Grieco M, Berlingieri MT, Vecchio G, Fusco A: The TRK and RET tyrosine kinase oncogenes cooperate with ras in the neoplastic transformation of a rat thyroid epithelial cell line. Cell Growth Differ 1993, 4:77-84
41. Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, Radice MT, Pierotti MA: The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site for phospholipase Cgamma. Mol Cell Biol 1996, 16: 2151-2163
42. Durick K, Wu RY, Gill GN, Taylor SS: Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain. J Biol Chem 1996, 271:12691-12694
43. De Vita G, Zannini M, Cirafici AM, Melillo RM, Di Lauro R, Fusco A, Santoro M: Expression of the RET/PTC 1 oncogene impairs the activity of TTF-1 and Pax-8 thyroid transcription factors. Cell Growth Differ 1998, 9:97-103
44. Fischer AH, Chaddee DN, Wright JA, Gansler TS, Davie JR: Ras-associated nuclear structural change appears functionally significant and independent of the mitotic signaling pathway. J Cell Biochem 1998, 70:130-140
45. Thommes P, Blow JJ: The DNA replication licensing system. Cancer Surv 1997, 29:75-90
46. Yang L, Guan T, Gerace L: Lamin-binding fragment of LAP2 inhibits increase in nuclear volume during the cell cycle and progression into S phase. J Cell Biol 1997, 139:1077-1087
47. Ohno M, Fornerod M, Mattaj IW: Nucleocytoplasmic transport: the last 200 nanometers. Cell 1998, 92:327-336
48. Ye Q, Worman HJ: Interaction between an integral protein of the nuclear envelope inner membrane and human chromodomain proteins homologous to Drosophila HP1. J Biol Chem 1996, 271:14653-14656
49. Ye Q, Callebaut I, Pezhman A, Courvalin JC, Worman HJ: Domain-specific interactions of human HP1-type chromodomain proteins and inner nuclear membrane protein LBR. J Biol Chem 1997, 272:14983-14989